参松养心胶囊联合美托洛尔治疗冠心病室性早搏的临床效果

Clinical effect of Shensong Yangxin Capsules combined with Metoprolol in the treatment of ventricular premature beat in coronary heart disease

目的探讨参松养心胶囊联合美托洛尔治疗冠心病室性早搏的临床效果。方法选取2019年12月至2021年4月黑龙江省中医药科学院心内科收治的60例冠心病室性早搏患者作为研究对象,按照随机数字表法分为对照组(30例)与治疗组(30例)。对照组采用西医常规结合美托洛尔治疗,治疗组在对照组基础上加用参松养心胶囊治疗。比较两组的中医证候评分,血浆N末端B型利钠肽原(NT-proBNP)、血管紧张素Ⅱ(AngⅡ),24 h早搏数量及心功能指标[左心室收缩末期内径(LVESD)、左心室舒张末期内径(LVEDD)、左心室射血分数(LVEF)]。结果两组治疗前的中医证候评分比较,差异无统计学意义(P>0.05);治疗后,两组中医证候评分均低于治疗前,且治疗组低于对照组,差异有统计学意义(P<0.05)。两组治疗前的NT-proBNP、AngⅡ水平比较,差异无统计学意义(P>0.05);治疗后,两组血清NT-proBNP、AngⅡ水平均低于治疗前,且治疗组低于对照组,差异有统计学意义(P<0.05)。两组治疗前的24 h早搏数量比较,差异无统计学意义(P>0.05);治疗后,两组24 h早搏数量少于治疗前,且治疗组24 h早搏数量少于对照组,差异有统计学意义(P<0.05)。两组治疗前的心功能指标比较,差异无统计学意义(P>0.05)。治疗后,两组的LVESD、LVEDD低于治疗前,LVEF高于治疗前,且治疗组LVESD、LVEDD低于对照组,LVEF高于对照组,差异有统计学意义(P<0.05)。结论参松养心胶囊联合美托洛尔治疗冠心病室性早搏效果明显,能改善中医临床症状,改善NT-proBNP、AngⅡ指标,减少早搏次数,提高心功能,值得推广。

Objective To investigate the clinical effect of Shensong Yangxin Capsules combined with Metoprolol in the treatment of premature ventricular contractions in coronary heart disease.Methods A total of 60 patients with premature ventricular beats of coronary heart disease admitted to the Department of Cardiology,Heilongjiang College of Traditional Chinese Medicine From December 2019 to April 2021 were selected as the research subjects,and were divided into control group(30 cases)and treatment group(30 cases)according to random number table method.The control group was treated with conventional western medicine combined with Metoprolol,and the treatment group was treated with Shensong Yangxin Capsules on the basis of the control group.Traditional Chinese medicine(TCM)syndrome score,plasma N-terminal B-type natriuretic peptide(NT-proBNP),angiotensinⅡ(AngⅡ),number of 24 h premature pulse and cardiac function indexes(left ventricular end systolic diameter[LVESD],left ventricular end diastolic diameter[LVEDD],left ventricular ejection fraction[LVEF])were compared between the two groups.Results There was no significant difference in TCM syndrome score between the two groups before treatment(P>0.05).After treatment,TCM syndrome scores of both groups were lower than before,and the treatment group was lower than the control group,the difference was statistically significant(P<0.05).There was no significant difference in the levels of NT-proBNP and AngⅡbetween two groups before treatment(P>0.05).After treatment,the serum levels of NT-proBNP and AngⅡin both groups were lower than before,and the treatment group was lower than the control group,the differences were statistically significant(P<0.05).There was no significant difference in the number of premature pulse 24 h before treatment between the two groups(P>0.05).After treatment,the number of 24 h premature pulse in both groups was less than before,and the number of 24 h premature pulse in the treatment group was less than the control group,the difference was statistically significant(P<0.05).There was no significant difference in cardiac function indexes between the two groups before treatment(P>0.05).After treatment,LVESD and LVEDD in the two groups were lower than before,and LVEF was higher than before,and LVESD and LVEDD in the treatment group were lower than the control group,and LVEF was higher than the control group,the differences were statistically significant(P<0.05).Conclusion Shensong Yangxin Capsules combined with Metoprolol has obvious effect in the treatment of ventricular premature beat of coronary heart disease,which can improve the clinical symptoms of traditional Chinese medicine,improve NT proBNP and AngⅡindexes,reduce the number of premature beats and improve cardiac function,which is worthy of promotion.